The National Alkaptonuria Centre 


 

Many people diagnosed with alkaptonuria (AKU), have difficulty accessing efficient and effective care to treat their AKU. For some, there has been a lack of local expertise and knowledge when dealing with such a rare disease, resulting in the failure to detect complications of AKU and an inability to make appropriate treatments available.

The Robert Gregory National Alkaptonuria Centre exists to change this. It is needed to ensure that everyone with AKU has access to a knowledgeable team of specialists who can manage their care efficiently. 

The National AKU Centre was established by the Department of Health (National Specialised Services Commissioning Group) and opened to patients on 18th June 2012. The service was set up to provide assessments and treatment for people with AKU and is based at The Royal Liverpool University Hospital. It is a free NHS service open to anyone over the age of 16 who has been diagnosed with AKU and living in England or Scotland.

Patients who attend the National AKU Centre will receive: 

  • A full health assessment and treatment of AKU
  • Access to the drug nitisinone
  • Advice on living with and managing the disease.

Referral to The National AKU Centre

Once a diagnosis of AKU has been confirmed a GP or other relevant medical professional can make a referral to the National Centre. Diagnosis is confirmed by measuring the homogentisic acid levels in a blood or urine test. The referral is assessed by the team in Liverpool and the person is then invited to attend the National Centre.

The National AKU Centre can accommodate up to five patients per month and anyone attending is expected to return for review on an annual basis at the same time each year. The average stay at the Centre is three to four days.

Referrals from Wales

Wales has its own referral process for accessing the NAC. In the first instance, a GP or relevant physician must follow the appropriate clinical gateway. For AKU, a person has to be referred to the Clinical Gatekeeper based at Cardiff University Hospital. He will determine whether the specialist services needed to meet an individual’s needs is available in Wales. If it is deemed that such services are not available a referral to the NAC is agreed and the Gatekeeper will apply to the Welsh Health Specialised Services Committee for funding. If funding is agreed, the Gatekeeper can make a direct referral to the NAC.

Nitisinone is a drug currently licensed for another rare disease and it is thought to be effective in treating patients with AKU. All English and Scottish patients who attend the National AKU Centre are given access to nitisinone. At this time funding for patients in Wales and Northern Ireland is not available for accessing nitisinone.

If you would like to know more about the National Alkaptonuria Centre, please contact Lesley Harrison by emailing her at [email protected] or giving her a call on 07586759028. 

Published: 24.07.16 Next Review Date: 24.07.19


 



AKU Twitter

AKU Blog

Scientists for a Day: AKU Outreach in Italy
18-Apr-2018

The University of Siena (https://en.unisi.it/) is a valued member of DevelopAKUre (http://ww.. ...more

Findacure: Communication and Rare Diseases
11-Apr-2018

There are over 7,000 identified rare diseases. Eighty per cent of them are genetic, like AKU.. ...more

SHCA: Our Voice
04-Apr-2018

On 21st March, Reece Edmends, our Admin and Communications Officer, went to a meeting of the.. ...more

Publicising our Work: Nick Sireau
27-Mar-2018

Dr. Nick Sireau is CEO of the AKU Society and Chair of Trustees. After his two sons were.. ...more

Brexit and AKU
14-Mar-2018

In 2019, the AKU Society’s international clinical trial, DevelopAKUre (http://www.developa.. ...more